Replies to post #46975 on Biotech Values

[DewDiligence]

>…with the side effects of gemzar you have a hard time convincing me that it is of any great benefit<

You are contradicting yourself. If taking chemotherapy is an awful thing—as you assert—then surely delaying the need for additional chemo, which Gemzar did handily in the pivotal ovarian trial—is a meaningful QoL benefit.

[DewDiligence]

>The fda should cut dendreon some slack because if it really does improve survival by 23% that would be remarkable…<

If it really does? You do not sound especially confident here.

>…and a shame that patients are now deprived of that chance.<

This is an investment forum. If you want to help cancer patients, there are many worthy charitable organizations who would gladly accept your donation. Regards, Dew

[onco]

you do not sound like an oncologist to me. what do you treat them with little buddy?

[poorgradstudent]

>If you think that pfs for gemzar is significant then you cant see the forrest through the trees<

The HR was 0.72. You frequently refer to the median numbers, and in that metric, it was 8.6 months for the gemzar / carbo arm versus 5.8 months for the carbo arm, or a gain of 2.8 months.

Not really sure what your gripe is with Gemzar.